Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

3Com Corp (COMS) 51job Inc (JOBS) Actions Semiconductor Co Ltd (ACTS) Aeropostale Inc (ARO) Companhia de Bebidas das Americas (ABV) American Italian Pasta Co (AIPC) American States Water Co (AWR) Amkor Technology Inc (AMKR) Anworth Mortgage Asset Corp (ANH) Asbury Automotive Group Inc (ABG) Ashland Inc (ASH) Associated British Foods Plc (ASBFY) AudioCodes Ltd (AUDC) Baidu Inc (BIDU) Banco Santander SA (STD) Bank of Montreal (BMO) Barnes & ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Electrolux AB (ELUXY) APAC Customer Services Inc (APAC) BCE Inc (BCE) BNP Paribas SA (BNPQY) Cardtronics Inc (CATM) Clearwater Paper Corp (CLW) Comcast Corp (CMCSK) Credit Suisse Group AG (CS) Diageo Plc (DEO) Dollar Tree Inc (DLTR) Flamel Technologies SA (FLML) Hill-Rom Holdings Inc (HRC) Jones Apparel Group Inc (JNY) Legal & General Group Plc (LGGNY) Memsic Inc (MEMS) Netflix Inc (NFLX) Novo Nordisk A/S (NVO) Ocwen Financial Corp (OCN) Pegasystems Inc (PEGA) Rent-A-Center Inc (RCII) ScanSource Inc (SCSC) Signet Jewelers Ltd (SIG) Universal Electronics Inc (UEIC) Wyndham Worldwide Corp (WYN) View the entire Zacks #1 Rank List.

"ELUXY" Free Stock Analysis: Buy? Sell? Hold?...

Highlights include Novo Nordisk (NVO), Alkermes, Inc. (ALKS), Eli Lilly & Co. (LLY) and Amylin Pharmaceuticals, Inc. (AMLN).  Early this morning, Amylin Pharmaceuticals, Inc. (AMLN), Eli Lilly (LLY) and Alkermes (ALKS) announced that a New Drug Application (NDA) for Exenatide once weekly for type II diabetes has been submitted to the US FDA. Exenatide once weekly is an investigational sustained release medication for type II diabetes that is injected subcutaneously and administered only once a week. Exenatide is the active ingredient in Byetta injection, which is currently available on the market for people with type II diabetes who are unable to achieve good glycemic control with common oral therapies. Exenatide once weekly is co-developed by Amylin, Eli Lilly and Alkermes.Following the news, shares of the three companies all shot up, with Alkermes shares up the most at ...

Highlighted companies include Novo Nordisk (NVO), Alkermes (ALKS), Eli Lilly (LLY) and Amylin (ALMN).

Late Thursday, an FDA panel reviewing Novo Nordisk's (NVO) Liraglutide application for type II diabetes expressed concern over a study that indicated it might trigger thyroid cancer tumors in rodents.

Alkermes (ALKS) and Eli Lilly (LLY)/Amylin (ALMN) are also co-developing a similar drug exenatide LAR, a long-acting version of Amylin's popular medication Byetta for type II diabetes.

Both liraglutide and exenatide belong to the same class of drugs called GLP-1s. So far, according to data from both preclinical and clinical studies, we think Exenatide LAR may have a better safety profile than liraglutide, but we are not sure if the FDA will exert tough rule on the safety concerns of Exenatide.

Currently, Exenatide is under 4 phase III studies (DURATION-1, 2, 3 and 4). The extension of

...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Chinacast Education Corp (CAST) Comverse Technology Inc (CMVT) CPFL Energia SA (CPL) Hansen Natural Corp (HANS) Novo Nordisk A/S (NVO) Shaw Communications Inc (SJR) View the entire Zacks #1 Rank List.

Zacks Investment Research

Neose Technologies, Inc. (Nasdaq GM: NTEC), a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, recently announced that the company has signed definitive asset purchase agreements with Novo Nordisk A/S (NVO) and BioGeneriX AG, providing for the sale of substantially all of the assets of Neose in all-cash transactions for a purchase price of approximately $43 million.

Pending stockholder approval, the preliminary estimate of aggregate distribution amounts represents $0.27 to $0.45 per share of common stock. Pursuant to the terms of the common stock purchase warrants issued in connection with the company’s March 2007 equity financing, each warrant holder has an option to receive a cash payment within 30 days of the closing of the asset sales in exchange for such holder’s warrants.

Neose Technologies’ president and chief executive officer, George J. Vergis, Ph.D., commented, “The announcement

...